Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 5;26(15):7546.
doi: 10.3390/ijms26157546.

Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer

Mihai Ioan Pavalean  1   2 , Maria Dobre  3 , Iulia Andreea Pelisenco  3 , Victor Lucian Madan  1   2 , Elena Milanesi  1   3 , Mihail Eugen Hinescu  1   3
Affiliations

Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer

Mihai Ioan Pavalean et al. Int J Mol Sci. .

Abstract

Bladder cancer (BC) is the most frequent cancer of the urinary system and one of the most common malignancies in the world. In the last decade, many studies have been conducted to better understand the pathophysiological mechanisms of BC to find innovative markers for disease monitoring and treatment. In this study, we aim to identify miRNAs whose expression is associated with specific tumoral characteristics and risks of disease progression. Forty-one BC patients were enrolled in this study. The expression of 84 miRNAs was evaluated by qRT-PCR analysis on tumoral and peritumoral tissues. The results highlighted the association of the miRNA-17-92 cluster with BC, with miR-17-5p, miR-18a-5p, miR-19a-3p, and miR-20a-5p (members of this cluster) being upregulated in the tumoral tissue and correlated with muscle invasion and tumor grading. Taken together, our study identified a panel of 26 dysregulated miRNAs in BC, some of which may be associated with aggressiveness and the risk of progression of this malignancy.

Keywords: bladder cancer; miRNA-17-92 cluster; miRNAs; muscle invasion; risk of progression.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
miRNAs found to be differentially expressed between samples with muscle-invasive bladder cancer (MIBC; N = 7) and those with non-muscle-invasive bladder cancer (NMIBC; N = 25). Bar graphs represent the mean of the 2−ΔCt values, and error bars represent the standard error. Statistical significance between the two BC groups was calculated using the Mann–Whitney test.
Figure 2
Figure 2
miRNAs found differentially expressed in non-muscle-invasive BC samples comparing tumors with low and intermediate risk (L-I Risk; N = 11) vs. high risk (H Risk; N = 14). Bar graphs represent the mean of the 2−ΔCt values, and error bars represent the standard error. Statistical significance between the two BC groups was calculated using the Mann–Whitney test.
Figure 3
Figure 3
The graph shows miR-18a-5p as differentially expressed among the three BC groups (G1 = grade 1; G2 = grade 2, G3 = grade 3). Bar graphs represent the mean of the 2−ΔCt values, and error bars represent the standard error. The p value has been calculated using Kruskal–Wallis test followed by pairwise comparisons using Dunn’s test.
See this image and copyright information in PMC

References

    1. Qin C., Tian Q., Zhou H., Qin Y., Zhou S., Wu Y., Tianjiao E., Duan S., Li Y., Wang X., et al. Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System. J. Magn. Reson. Imaging. 2024;60:54–64. doi: 10.1002/jmri.29053. - DOI - PubMed
    1. Bray Bsc F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. GLOBOCAN 2022: Bladder Cancer 9th Most Common Worldwide—World Bladder Cancer Patient Coalition. [(accessed on 17 July 2025)]. Available online: https://worldbladdercancer.org/news_events/globocan-2022-bladder-cancer-...
    1. Lobo N., Hensley P.J., Bree K.K., Nogueras-Gonzalez G.M., Navai N., Dinney C.P., Sylvester R.J., Kamat A.M. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur. Urol. Oncol. 2022;5:84–91. doi: 10.1016/j.euo.2021.11.006. - DOI - PMC - PubMed
    1. Grabe-Heyne K., Henne C., Mariappan P., Geiges G., Pöhlmann J., Pollock R.F. Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer: An Overview of Epidemiology, Burden, and Unmet Needs. Front. Oncol. 2023;13:1170124. doi: 10.3389/fonc.2023.1170124. - DOI - PMC - PubMed

LinkOut - more resources